Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2025 | $8.00 | Overweight | KeyBanc Capital Markets |
| 8/16/2022 | Overweight → Neutral | JP Morgan | |
| 3/7/2022 | $11.00 → $10.00 | Equal-Weight | Morgan Stanley |
| 2/15/2022 | $24.00 → $11.00 | Equal-Weight | Morgan Stanley |
| 11/15/2021 | $26.00 → $24.00 | Equal-Weight | Morgan Stanley |
| 8/9/2021 | Outperform | Cowen | |
| 8/9/2021 | $26.00 | Equal-Weight | Morgan Stanley |
| 8/9/2021 | $28.00 | Buy | Stifel |
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar
LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S
MALVERN, Pa., April 4, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery services, today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company's next stage of growth. "We are thrilled to welcome Rich, a seasoned healthcare finance and operations executive, to the Executive Committee of Reaction Biology," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology. "Having managed large, global biopharmaceut
KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00
JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral
Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $10.00 from $11.00 previously
Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa
LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after
LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants (i) on March 3, 2025, of 50,000 restricted stock units ("RSUs") of the Company's Class A common stock ("Common Stock") as a material inducement to employment of one new employee and (ii) on March 10, 2025, of non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the "Options") and 174,000 RSUs as a material inducement to employment to two
Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa
LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after
Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increased 24 percentage points compared to 2023.Announces global Distribution and Collaboration Agreement with MilliporeSigma LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
DEFA14A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)